Home >> Stock >> Grupo Aval Acciones y Valores S.A. ADR (Each representing 20 preferred shares) >> Metrics
Grupo Aval Acciones y Valores S.A. is a financial services group. It provides a comprehensive range of financial services and products ranging from traditional banking services, such as making loans and taking deposits, to pension and severance fund management. The company also provides general purpose loans, foreign exchange services, documentation services, guarantees, auto financing, payroll loans, and credit cards, as well as various deposit and basic treasury products. It provides fiduciary services; merchandise storage and deposit, customs agency, cargo management, and merchandise distribution; brokerage services, fund management, portfolio management, securities management, and capital markets consulting services; and investment banking, treasury, and private banking services. Grupo Aval Acciones Y Valores S.A. is based in Bogot', Colombia....
+See More2019-01-19 12:38:00 Saturday ET
U.S. government shuts down again because House Democrats refuse to spend $5 billion on the border wall that would give President Trump great victory on his
2019-02-11 09:37:00 Monday ET
Corporate America uses Trump tax cuts and offshore cash stockpiles primarily to fund share repurchases for better stock market valuation. Share repurchases
2023-02-28 11:30:00 Tuesday ET
The Biden Inflation Reduction Act is central to modern world capitalism. As of 2022-2023, global inflation has gradually declined from the peak of 9.8% d
2020-02-05 10:28:00 Wednesday ET
Our proprietary AYA fintech finbuzz essay shines light on the modern collection of business insights with executive annotations and personal reflections. Th
2018-05-17 07:41:00 Thursday ET
Has America become a democratic free land of crumbling infrastructure, galloping income inequality, bitter political polarization, and dysfunctional governa
2019-01-10 17:31:00 Thursday ET
The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be